Skip to main
VSTM

Verastem (VSTM) Stock Forecast & Price Target

Verastem (VSTM) Analyst Ratings

Based on 6 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Verastem is a late-stage development biopharmaceutical company with a strong pipeline of novel anticancer agents focused on RAF/MEK and FAK inhibition. Positive recent clinical data, including a net product revenue beat in 2Q26 and the strengthening of their balance sheet, suggest strong potential for future growth and profitability. The company's emphasis on targeting critical signaling pathways in cancer, such as RAF/MEK and FAK inhibition, along with its focus on advancing new medicines for patients battling cancer, make it an attractive investment for the future.

Bears say

Verastem is facing challenges with market saturation and high competition due to the presence of several other biopharmaceutical companies in the cancer treatment sector. Despite an increase in net product revenue in the past quarter, the company has not yet reached financial self-sustainability and relies heavily on non-dilutive financing and milestone payments for funding. Furthermore, the upcoming confirmatory Phase 3 study for Avmapki and Fakzynja is not expected to yield topline data until mid-2027, potentially causing further delays and hindering the company's growth potential.

Verastem (VSTM) has been analyzed by 6 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Verastem (VSTM) Forecast

Analysts have given Verastem (VSTM) a Strong Buy based on their latest research and market trends.

According to 6 analysts, Verastem (VSTM) has a Strong Buy consensus rating as of Aug 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.83, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.83, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Verastem (VSTM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.